Myocardial infarction in elderly pacients

1.Widimský P, Špaček R. Infarkt myokardu – úvodní poznámky. In: Aschermann M et al (eds). Kardiologie. Praha: Galén 2004: vol. 1, 688-689.

2.Dušek J et al. Pokles celkové a sezónní úmrtnosti pro infarkt myokardu v České republice v letech 1994-2003. Cor Vasa 2006; 48(4): 21.

3.ÚZIS – ČR, Aktuální informace č. 13/2004.

4.ÚZIS – ČR, Informace ze zdravotnictví Moravskolslezského kraje č. 20/2003.

5.ÚZIS – ČR, Informace ze zdravotnictví Královéhradeckého kraje č. 02/2002.

6.Burke AP, Kolodgie FD et al. Healed plaque ruptures and sudden coronary death, evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-940.

7.Gotwalles Y et al. Acute STEMI in old pateints. The real life. Ann Cardiol Angeiol 2004; 53(6): 305-313.

8.Helmy T, Patel AD, Wenger NK et al. Evidence-based management of coronary artery disease in the elderly – current prospectives. Med Gen Med 2005; 7(2): 75.

9.Internetová dokumentace - www.eamos.cz

10.LaCroix AZ, Guralnik JM, Curb JD et al. Chest pain and coronary heart disease mortality among older men and women in three communites. Circulation 1990; 81: 437-446.

11.Dangelser G et al. Acute ST – elevation myocardial infarction in the elderly (> 75 years). Results from a regional multicenter study. Presse Med 2005; 34(14): 983-989.

12.Wehrens XH, Doevendans PA. Cardiac rupture complicating myocardial infarction. Int J Cardiol 2004; 95(2-3): 285-292.

13.Joussein-Remacle S, Delarche N, Bader H et al. Risk factors in young population with acute myocardial infarction: one year prospective study. Ann Cardiol Angeiol 2006; 55(4): 204-209.

14.Miyamoto S, Goto Y, Sumida H, Yasuda et al. Risk factors and physicial aktivity levels at the onset of acute myocardial infarction in young men. J Cardiol 2000; 36(2): 75-83.

15.Internetová dokumentace – www.tasc-pad.org

16.Hertzer NR, Beven EG, Young JR et al. Coronary artery disease in peripheral vascural patients: a classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-233.

17.Kronmal RA, Barzilay JI, Smith NL et al. Mortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study, 1989-2001. PLoS Med 2006; 3(10): 400.

18.Newman AB, Siscovick DS, Manolio TA. Ankle-arm index as a marker of atherosclesrosis in the Cardiovascular Health Study. Circulation 1993; 88: 837-845.

19.Hennerici M, Aulich A, Sandeman W. Incidence of asymptomatic extracranial arterial disease. Stroke 1981; 12: 750-758.

20.Widimský P, Janoušek S, Vojáček J. Doporučení pro diagnostiku a léčbu akutního infarktu myokardu, (Q typ/ s elevacemi ST/ s raménkovým blokem). guidelines České kardiologické společnosti č. 24, internetová dokumentace – www.kardio.cz, resp. Cor Vasa 2002; 44(7/8): K123-K143.

21.De Gevigney G, Delahaye F, Staat P. Heart failure and myocardial infarction in the elderly. For its more specific management. Presse Med 2003; 32(22): 1033-1038.

22.Wilbert S, Aronow WS. Treatment of unstable Angina Pectoris/Non-ST-segment elevation myocardial infarction in elderly patiens. J Gerontol A Bio Sci Med Sci 2003; 58(10): 927-933.

23.Mangoni AA, Jackson SH. The implication of growing evidence base for drug use in elderly patients. Part 3. – beta adrenoreceptor blockers in heart failure and thrombolytics in acute myocardial infarction. Br J Clin Pharmacol 2006; 61(5): 521-528.

24.Levy P, Lechat P, Leizovicz A et al. A cost minimalization of heart failure therapy with bisoprolol in the French settings an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drug Ther 1998; 12(3): 301-305.

25.Domanski MJ, Krause-Steinrauf H, Massie BM et al. A komparativ analysis from 4 trials of beta – blocker therapy for heart failure: BEST, CIBIS II, MERIT-HF and COPERNICUS. J Card Fail 2003; 9(5): 354-363.

26.Mc Queen MJ, Lonn E, Gerstain HC et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Incest Suppl 2005; 240: 143-156.

27.Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73(1): 237-246.

28.Sica DA. New considerations relating to vlase effect with angiotenzin-converting enzyme inhibitors – the PEACE study. J Clin Hypertens 2005; 7(3): 188-193.

29.Pitt B. Effect of aldosteron blockade in patiens with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrionol 2004; 217(1-2): 53-58.

30.White HD, Aylward PE, Huong Z et al. Mortality and morbidity Romain high despote captopril and/or Valsartan therapy in elderly patints with left ventricular systolic dysfunction, heart failure or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005; 112(22): 3391-3399.

31.Pfeffer MA, McMurray JJ, Velaquez EJ et al. Vlasartan, cpatopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.

32.Haffner SM, Alexandr CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patiens with coronary heart disease and diabetes or impaired fasting glukose levels: subgroup analyse in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-2667.

33.Philippe F. Value and role of lipid lowering therapy for cardiovascular prevention in the elderly. Ann Cardiol Angeiol 2003; 52(4): 246-253.

34.Ray KK, Canon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 2004; 15(6): 637-643.

35.Evans M, Roberts A Dares S et al. Medical lipid regulating therapy: current evidence, ongoing trials and future developments. Drugs 2004; 64(11): 1181-1196.

36.Mehta RH, Havaji KJ, Cox D et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patiens with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42(10): 1739-1746.

37.Mehta AB, Abhyankar AD. Sion thrombolysis trial – randomised trial of intravenous thrombolysis and primary percutaneus transluminal coronary angiography for acute myocardial infarction (AMI) – feasibility phase data of angioplaty limb. J Assoc Physicians India 1994; 42(1): 43-44.

38.Fintel DJ, Ledley GS. Management of patiens with non ST-segment elevation acute coronary syndroms: insight from the PURSUIT trial. Clin Cardiol 2000; 23(Suppl 5): 1-12.

39.Tetros SJ, Snapin SM, Wan Y et al. Tirofiban therapy for patiens with acute coronary syndromes and prior coronary vypase grafting in the PRISM-PLUS trial. Am J Cardiol 2004; 93(7): 843-847.

40.Chan AW, Moliterno DJ. Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V and TARGET trials. Curr Opin Cardiol 2001; 16(6): 375-383.

41.Mc Kay RG, Boden WE. Small peptide GP IIb/III receptor inhibitors as upstream therapy in non ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS and PARAGON trials. Curr Opin Cardiol 2001; 16(6): 364-369.

42.Benner JS et al. Long-term perzistance in use of statin therapy in elderly patiens. JAMA 2002; 288: 455-461.

43.Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. N Engl J Med 1999; 341: 625-634.

44.Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patinets with coronary hearth disease: a systemic review. JAMA 2003; 290: 86-97.

45.Hanna IR, Wenger NK. Secondary prevention of coronary hearth disease in elderly patiens. Am Fam Physician 2005; 71(12): 2289-2296.